MedinCell S.A. (MDCLF)
USD 6.98
(0.0%)
USD 6.98
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -18.61 Million EUR | 29.53% |
| 2023 | -26.41 Million EUR | -23.11% |
| 2022 | -21.44 Million EUR | -36.32% |
| 2021 | -18.12 Million EUR | 12.39% |
| 2020 | -18.07 Million EUR | -17.86% |
| 2019 | -15.22 Million EUR | -137.61% |
| 2018 | -6.4 Million EUR | -193.18% |
| 2017 | -3.03 Million EUR | -377.28% |
| 2016 | 788 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -9.29 Million EUR | 0.0% |
| 2024 Q1 | -4.24 Million EUR | 28.52% |
| 2024 Q3 | -5.77 Million EUR | -35.97% |
| 2024 FY | - EUR | 15.98% |
| 2024 Q4 | -5.77 Million EUR | 0.0% |
| 2023 Q2 | -12.52 Million EUR | -124.23% |
| 2023 Q4 | -13.65 Million EUR | -129.75% |
| 2023 Q1 | -5.58 Million EUR | 58.88% |
| 2023 FY | - EUR | -23.11% |
| 2023 Q3 | -5.94 Million EUR | 52.54% |
| 2022 Q1 | -5.39 Million EUR | 36.33% |
| 2022 FY | - EUR | -36.32% |
| 2022 Q4 | -13.57 Million EUR | -123.52% |
| 2022 Q3 | -6.07 Million EUR | 53.45% |
| 2022 Q2 | -13.05 Million EUR | -141.71% |
| 2021 Q1 | -3.87 Million EUR | 66.69% |
| 2021 Q4 | -8.48 Million EUR | -63.43% |
| 2021 Q3 | -5.18 Million EUR | 43.71% |
| 2021 Q2 | -9.22 Million EUR | -138.09% |
| 2021 FY | - EUR | 12.39% |
| 2020 FY | - EUR | -17.86% |
| 2020 Q2 | -9.48 Million EUR | -154.1% |
| 2020 Q3 | -5.44 Million EUR | 42.56% |
| 2020 Q4 | -11.62 Million EUR | -113.34% |
| 2020 Q1 | -3.73 Million EUR | 13.76% |
| 2019 Q3 | -4.32 Million EUR | -38.42% |
| 2019 FY | - EUR | -137.61% |
| 2019 Q2 | -3.12 Million EUR | 0.0% |
| 2019 Q1 | -3.12 Million EUR | -132.7% |
| 2019 Q4 | -4.32 Million EUR | 0.0% |
| 2018 Q3 | -1.34 Million EUR | 29.0% |
| 2018 Q4 | -1.34 Million EUR | 0.0% |
| 2018 FY | - EUR | -193.18% |
| 2018 Q1 | -1.89 Million EUR | 0.0% |
| 2018 Q2 | -1.89 Million EUR | 0.0% |
| 2017 FY | - EUR | -377.28% |
| 2016 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 73.796% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -213.953% |
| SQZ Biotechnologies Company | -64.14 Million USD | 70.98% |
| Evofem Biosciences, Inc. | -17.37 Million USD | -7.162% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 119.794% |
| Mesoblast Limited | -62.38 Million USD | 70.165% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1111.81% |
| Genus plc | 73.7 Million USD | 125.256% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -181.539% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -424.782% |
| Marizyme, Inc. | -34.28 Million USD | 45.702% |
| ContraFect Corporation | -64.99 Million USD | 71.363% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -112.198% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -311.251% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1227.857% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -603.89% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -701.009% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -3493.117% |
| Accustem Sciences Inc. | -3.74 Million USD | -396.848% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 61.403% |
| EV Biologics, Inc. | -1.26 Million USD | -1368.987% |
| Q BioMed Inc. | -617.62 Thousand USD | -2913.788% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 621.109% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2843.362% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -714.799% |
| Biomind Labs Inc. | -1.03 Million USD | -1699.238% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 288.458% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -159.926% |
| Skye Bioscience, Inc. | -13.54 Million USD | -37.398% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -1151.435% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -74356.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -379.209% |
| IMV Inc. | -35.52 Million USD | 47.601% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -17.292% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -643.976% |
| GB Sciences, Inc. | -1.41 Million USD | -1210.951% |
| Alpha Cognition Inc. | -9.7 Million USD | -91.786% |
| HST Global, Inc. | -5303.00 USD | -350908.863% |
| CSL Limited | 4.78 Billion USD | 100.389% |
| Halberd Corporation | -74.27 Thousand USD | -24959.573% |
| Enzolytics Inc. | -2.12 Million USD | -777.179% |
| Resverlogix Corp. | -11.74 Million USD | -58.525% |
| Affymax, Inc. | -14.29 Million USD | -30.213% |
| SYBLEU INC | -141.57 Thousand USD | -13048.173% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -507.702% |
| argenx SE | -216.02 Million USD | 91.383% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 66.364% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1629.499% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -1141.839% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 5013.368% |
| AVAX Technologies, Inc. | -6.11 Million USD | -204.516% |
| Zenith Capital Corp. | -8.6 Million USD | -116.291% |
| Genscript Biotech Corporation | -248.71 Million USD | 92.516% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -106748.057% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -660.854% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -10474.673% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 53.039% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -543.565% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1679.01% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 276929.268% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -963.658% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -869.019% |
| BioStem Technologies, Inc. | -7.55 Million USD | -146.424% |
| ONE Bio Corp. | 13.61 Million USD | 236.737% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -10178.98% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -804.91% |
| Agentix Corp. | -1.37 Million USD | -1256.947% |
| LadRx Corporation | 412.28 Thousand USD | 4614.86% |
| Cell Source, Inc. | -4.27 Million USD | -335.667% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -4968.882% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1369.752% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1886.661% |
| NovAccess Global Inc. | -1.03 Million USD | -1698.807% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 310.237% |
| Itoco Inc. | -1.86 Million USD | -895.936% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -4803.324% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1567.921% |
| Kadimastem Ltd | -2.62 Million USD | -609.272% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -7683.4% |
| CytoDyn Inc. | -18.02 Million USD | -3.245% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -23453.379% |
| Mobile Lads Corp. | -2.24 Million USD | -730.552% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -152111.955% |
| Qrons Inc. | -40.08 Thousand USD | -46340.957% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -3732.58% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 3629.169% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1857.308% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1652.714% |
| International Stem Cell Corporation | 202 Thousand USD | 9314.851% |
| Bioxytran, Inc. | -3.82 Million USD | -387.259% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -35260.942% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -656.073% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 48.106% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -41264.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -579.839% |
| Neutra Corp. | -181.24 Thousand USD | -10169.963% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 7.664% |
| PureTech Health plc | -11.62 Million USD | -60.093% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 7.658% |
| IXICO plc | -707 Thousand USD | -2532.815% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -142.212% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 61.498% |
| CSL Limited | 4.73 Billion USD | 100.393% |
| Cellectis S.A. | -92.63 Million USD | 79.906% |